FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Consensus Needs to Come Down on Intercept (ICPT) after FDA Review is Extended - Leerink
December 18, 2015 8:44 AM ESTLeerink Partners analyst, Joseph Schwartz noted that Intercept Pharmaceuticals (NASDAQ: ICPT) announced that the FDA has extended the PDUFA date for its priority review application of Obeticholic acid (OCA) in primary biliary cirrhosis/ cholangitis (PBC) by 3 mos. to May 29, 2016. ICPT stated that FDA had requested additional information, to which ICPT has... More
FDA Pushed Back Intercept Pharma's (ICPT) PDUFA Date; Seeks More Data - Baird Maintains Outperform
December 18, 2015 7:41 AM ESTBaird maintained an Outperform rating and $346.00 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following the company's announcement that the FDA pushed out its Prescription Drug User Fee Act (PDUFA) date for the priority review of obeticholic acid (OCA) in primary biliary cholangitis (PBC). The... More
